Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
Healthy Volunteers
NCT06997185

Communicating Uncertainties Associated With the Benefits and Risks of New Cancer Drugs

Led by London School of Economics and Political Science · Updated on 2025-05-30

3000

Participants Needed

1

Research Sites

3 weeks

Total Duration

On this page

Sponsors

L

London School of Economics and Political Science

Lead Sponsor

H

Harvard Medical School / Harvard Pilgrim Health Care Institute

Collaborating Sponsor

AI-Summary

What this Trial Is About

This nationally representative randomized survey of US adults will evaluate the effect of using brief statements to communicate different sources of uncertainty about the benefits and harms of new cancer drugs on participants' decisions and understanding.

CONDITIONS

Official Title

Communicating Uncertainties Associated With the Benefits and Risks of New Cancer Drugs

Who Can Participate

Age: 18Years +
All Genders
Healthy Volunteers

Eligibility Criteria

Eligible

You may qualify if you...

  • Adults 18 years of age and older
  • Adults fluent in English
  • Adults residing in the United States
Not Eligible

You will not qualify if you...

  • Participants who do not meet each of the 3 inclusion criteria

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Harvard Medical School and Harvard Pilgrim Health Care Institute

Boston, Massachusetts, United States, 02139

Actively Recruiting

Loading map...

Research Team

A

Avi Cherla

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

DOUBLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

OTHER

Number of Arms

5

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Communicating Uncertainties Associated With the Benefits and Risks of New Cancer Drugs | DecenTrialz